licensingAlzeCure licenses Alzheimer’s asset to QuantumCell in $2.2bn dealSwedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, … more ➔
M&AIpsen’s buying streak continues with €700m Memo dealParis-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than €700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeli … more ➔
StrategyInflaRx seeks to fill void left by Amgen’s Tavneos in EuropeInflaRx is preparing for discussions with regulators in Europe over two drugs that could provide an alternative to patients treated with Amgen’s Tavneos (avacopan), which is set to be removed from … more ➔
clinical dataGenmab shares rise following positive epcoritamab phase 3 dataGenmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement … more ➔
Start-upsmartbax extends pre-series A to €6.3 m for new antibioticMunich-based smartbax has secured additional financing to advance its lead antibiotic programme, building on a €4.7m pre-Series A first close announced in October 2025. more ➔
clinical dataAbivax answers safety questions with new dataAbivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing … more ➔
financeScancell plots reverse-merger path to NasdaqUK immunotherapy developer Scancell has confirmed talks to acquire Nasdaq-listed Neuphoria Therapeutics, in a move that could give the Oxford-based biotech a faster route to US public markets. more ➔
Start-upEMBL spin-off Epitome launches with €4MVienna-based Epitome Therapeutics has launched with €4 million in total financing to advance a new epigenome-editing platform designed to precisely control gene expression. more ➔
Watchlist8 European VC firms to watch in 2026European biotech enters 2026 in a strange, almost contradictory mood. The easy-money years are gone, the post-pandemic correction has done its damage, and investors are no longer rewarding science … more ➔
M&AIpsen buys Kartos in $1.75bn myelofibrosis pushParis-based Ipsen has agreed to acquire US biotech Kartos Therapeutics in a deal worth up to $1.75bn, adding a late-stage blood cancer programme to its growing oncology pipeline. more ➔
